Vidutolimod is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData, Phase II drugs for Merkel Cell Carcinoma have a 15% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vidutolimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CMP-001 (CYT-003) is under development for the treatment of recurrent or metastatic head and neck squamous cell carcinoma, head and neck cancer, hepatocellular carcinoma, merkel cell carcinoma, relapsed and refractory B and T cell Hodgkin lymphoma or Non-Hodgkin lymphoma, Oropharyngeal Cancer, oral cavity, hypopharynx, or larynx cancer, metastatic colorectal cancer, cutaneous squamous cell carcinoma (CSCC), advanced cutaneous melanoma, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), triple-negative breast cancer (TNBC), gastric cancer, platinum resistant ovarian cancer, bladder cancer, small cell lung cancer (SCLC), metastatic castration resistant prostate cancer and progressing tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT/PVNS). The drug candidate is administered through subcutaneous and intratumoral route. It consists of QbG10 with virus-like particle Qb filled with a synthetic immunostimulatory DNA sequence called G10. It acts by targeting Toll-like receptor 9. It was also under development for the treatment of allergic asthma, allergic rhinitis, allergic rhinoconjunctivitis, HBV infections and atopic dermatitis.
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick, Ireland. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
For a complete picture of Vidutolimod’s drug-specific PTSR and LoA scores, buy the report here.